SAN DIEGO, July 12, 2021–(Business WIRE)–Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been submitted in the District of Massachusetts on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) popular inventory among November 16, 2020 and March 22, 2021, inclusive (the “Class Period of time”). The case is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933, and is assigned to Choose William G. Younger. The Frequency Therapeutics class motion lawsuit charges Frequency Therapeutics and selected of its executives with violations of the Securities Trade Act of 1934. A identical lawsuit, captioned Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending in the District of Massachusetts.
If you suffered sizeable losses and want to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, please deliver your info by clicking listed here. You can also call legal professional J.C. Sanchez of Robbins Geller by calling 800/449-4900 or by using e-mail at [email protected]. Direct plaintiff motions for the Frequency Therapeutics course motion lawsuit need to be submitted with the court docket no later than August 2, 2021.
Scenario ALLEGATIONS: The Frequency Therapeutics course motion lawsuit alleges that, shortly right after launching the Phase Forex-322 2a demo, Frequency Therapeutics and its Chief Government Officer, defendant David L. Lucchino, uncovered that the Section 2a trial effects exposed no discernable variation between Forex-322 and the placebo. The Frequency Therapeutics course motion lawsuit additional alleges that, when Frequency Therapeutics’ inventory value remained artificially inflated, defendant Lucchino bought above 350,000 Frequency Therapeutics shares, pocketing about $10.5 million.
On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Period 2a effects, revealing that topics with mild to average serious sensorineural listening to loss did not reveal improvements in hearing actions versus placebo. On this information, Frequency Therapeutics’ stock price tag fell by nearly 78%, detrimental investors.
THE Direct PLAINTIFF Procedure: The Personal Securities Litigation Reform Act of 1995 permits any trader who obtained Frequency Therapeutics common inventory in the course of the Class Interval to look for appointment as guide plaintiff in the Frequency Therapeutics class action lawsuit. A guide plaintiff is frequently the movant with the biggest economic interest in the relief sought by the putative course who is also usual and sufficient of the putative course. A direct plaintiff functions on behalf of all other class associates in directing the Frequency Therapeutics course motion lawsuit. The guide plaintiff can find a law company of its choice to litigate the Frequency Therapeutics course action lawsuit. An investor’s skill to share in any opportunity foreseeable future recovery of the Frequency Therapeutics class motion lawsuit is not dependent on serving as guide plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the biggest U.S. law firm representing buyers in securities course steps. Robbins Geller lawyers have acquired a lot of of the most significant shareholder recoveries in heritage, together with the biggest securities class motion restoration ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Course Motion Solutions Leading 50 Report ranked Robbins Geller initially for recovering $1.6 billion for investors past year, extra than double the volume recovered by any other securities plaintiffs’ agency. Be sure to pay a visit to https://www.rgrdlaw.com/business.html for a lot more data.
Legal professional advertising and marketing.
Previous benefits do not ensure potential results.
Expert services may be performed by lawyers in any of our workplaces.
See supply version on businesswire.com: https://www.businesswire.com/news/home/20210712005829/en/
Contacts
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]
